Stefan Willemsen, CEO of bioMerieux, spoke to The Gray Sheet recently about President Obama's efforts to combat antibiotic resistance, the NIH and Barda's $20 million antibiotic resistant rapid point-of-care diagnostic competition, his company's real-time antibiotic resistance surveillance system and their acquisition of BioFire.
